WO1998048839A1 - Topical nasal antiinflammatory compositions - Google Patents
Topical nasal antiinflammatory compositions Download PDFInfo
- Publication number
- WO1998048839A1 WO1998048839A1 PCT/US1998/006483 US9806483W WO9848839A1 WO 1998048839 A1 WO1998048839 A1 WO 1998048839A1 US 9806483 W US9806483 W US 9806483W WO 9848839 A1 WO9848839 A1 WO 9848839A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- agent
- group
- nasal
- topical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Definitions
- Topical nasal antiinflammatory preparations are known in the art for the treatment of inflammatory conditions of the nasal mucous membranes, and in particular for relief of the symptoms of nasal and sinus conditions such as rhinitis.
- nasal and sinus conditions may be characterized by diverse symptoms requiring treatment with multiple therapeutic agents.
- allergic rhinitis may be characterized by rhinorrhea, nasal itching, sneezing, congestion and postnasal drip and treatment may require antihistamines, decongestants, antiallergics and anesthetics in addition to antiinflammatories.
- the use of multiple topical nasal preparations to administer multiple therapeutic agents suffers from significant disadvantages.
- the volume of liquid that can effectively be applied nasally is limited by the surface area of the nostril and the bioadhesiveness of the liquid.
- a sufficient contact time between topical preparations and the surface area of the nostril is required to assure adequate dosing of a therapeutic agent.
- spray formulations require a threshold surface tension to form droplets.
- the delivery volume per actuation is limited to the volume that will be retained in the nostril without premature drainage.
- multiple topical nasal preparations cannot be effectively administered simultaneously.
- Another disadvantage of the administration of multiple topical nasal preparations is patient inconvenience. Patient compliance may be compromised by the inconvenience of applying multiple spray products or nose drops. Patients complain when excess spray drains into their throats where it can be tasted, resulting in a need for flavor masking of bitter medicaments.
- the present invention provides topically applicable nasal compositions comprising a therapeutically effective amount of a topical antiinflammatory agent and a therapeutically effective amount of at least one agent suitable for topical nasal administration and selected from the group consisting of a vasoconstrictor, a neuramidinase inhibitor, an anticholinergic agent, a leukotriene inhibitor, an antihistamine, an antiallergic agent, an anesthetic, and a mucolytic agent.
- the present invention provides topically applicable nasal compositions comprising a topical antiinflammatory agent and at least one additional therapeutic agent.
- the present compositions are useful for the treatment of nasal and sinus conditions, for example allergic rhinitis or the common cold.
- the topical antiinflammatory agents in the compositions of the present invention are corticosteroids known in the art to suppress inflammation.
- the topical antiinflammatory agent is beclomethasone diproprionate, budesonide, dexamethasone, mometasone furoate, fluticasone proprionate or triamcinolone acetonide.
- the compositions contain a therapeutically effective amount of the selected antiinflammatory agent. Those of ordinary skill in the art can determine an amount that is therapeutically effective for the suppression of inflammation. The precise amount will depend upon the method of administration and the age, weight and condition of the subject to be treated. Generally the antiinflammatory agents are utilized in dosages known in the art to be therapeutically effective upon nasal administration.
- compositions of the invention further comprise at least one additional therapeutic agent, and thus allow the convenient administration of an antiinflammatory agent and at least one additional therapeutic agent in a single topical nasal composition.
- the additional therapeutical agent is suitable for topical nasal administration and is selected from the group consisting of a vasoconstrictor, a neuramidinase inhibitor, a leukotriene inhibitor, an anticholinergic agent, an antihistamine, an antiallergic agent, a local anesthetic and a mucolytic agent.
- the use of an additional therapeutic agent in combination with an antiinflammatory agent provides additive and synergistic effects in the treatment of nasal and sinus conditions.
- Vasoconstrictors suitable for topical nasal administration in the compositions of the present invention are oxymetazoline naphazoline, xylometazoline, and phenylephrine.
- Leukotriene inhibitors include zafirlukast, a selective, competitive receptor antagonist of the three leukotrienes C4, D4, and E4; pranlukast, a selective, competitive receptor antagonist of D4; and zileuton, a leukotriene inhibitor.
- A. neuramidinase inhibitor includes zanamivir (GG-167).
- Suitable antihistamines are diphenhydramine, chlorpheniramine, cetirizine terfenadine, fenofexadine, astemizole norastemizole, azelastine, and azatidine.
- Antiallergic agents include cromolyn sodium and nedocromil levocabastine.
- An anticholinergic agent useful in the compositions of the present invention is ipratropium bromide.
- Local topical anesthetics include dyclonine, pramoxine, and benzocaine.
- Mucolytic agents suitable for topical nasal administration are acetylcysteine, guaifenisin and mucocysteine. The therapeutically effect amount of foregoing agents can be determined by the ordinarily skilled artisan with regard to the known use of these agents in the art and taking into account the method of administration and the age, weight and condition of the subject to be treated.
- compositions of the present invention are formulated as aqueous solutions comprising an antiinflammatory agent and at least one additional therapeutic agent and further comprising a pharmaceutically acceptable nasal carrier.
- the formulation of pharmaceutical compositions is generally known in the art and reference can be conveniently made to standard text such as Remington's Pharmaceutical Sciences, 1985, 17th ed., Mack Publishing Co., Easton, Pennsylvania.
- Preferred nasal formulations are nose drops or nasal sprays containing a water buffered aqueous solution as a carrier.
- the compositions are preferably isotonic. Isotonic agents such as a sugars and sodium chloride are known in the art and may be included in the subject compositions.
- compositions of the present invention may also contain a humectant to increase viscosity and effect moisturization and ciliary vitality.
- Suitable humectants include glycerin, polyethylene glycol, propylene glycol and mixtures thereof.
- compositions including pharmaceutically acceptable preservatives, stabilizers, flavoring agents, and pH adjusters are known in the art and may be included in the present compositions.
- Another embodiment of the present invention provides preservative- free compositions comprising an anti-inflammatory agent and at least one additional therapeutic agent. Preservative-free compositions are preferred due to reduced sensitivity and increased patient acceptance. These can be prepared in unit dose or in systems which prevent contamination of the reservoir of solution.
- the compositions of the present invention can be conveniently administered nasally to a human subject in dosage unit form to elicit the desired therapeutic effect of the antiinflammatory agent and the additional therapeutic agents described above.
- the compositions may be administered in the form of a nasal spray or nose drops.
- Nasal sprays may be provided as squeeze bottles or metered dose manual nasal spray pumps designed to deliver the desired dose in one or two sprays, for example.
- the composition may also be administered as aerosol spray formulations, for example as metered dose pressurized aerosols containing propellants such as halogenated hydrocarbons.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002281789A CA2281789A1 (en) | 1997-04-30 | 1998-04-02 | Topical nasal antiinflammatory compositions |
AU68780/98A AU6878098A (en) | 1997-04-30 | 1998-04-02 | Topical nasal antiinflammatory compositions |
BR9809022-4A BR9809022A (pt) | 1997-04-30 | 1998-04-02 | Composições antiinflamatórias nasais tópicas |
JP54699898A JP2001524108A (ja) | 1997-04-30 | 1998-04-02 | 局所経鼻抗炎症組成物 |
EP98914420A EP0979105A1 (en) | 1997-04-30 | 1998-04-02 | Topical nasal antiinflammatory compositions |
IL13149298A IL131492A0 (en) | 1997-04-30 | 1998-04-02 | Topical nasal antiinflammatory compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4430697P | 1997-04-30 | 1997-04-30 | |
US60/044,306 | 1997-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998048839A1 true WO1998048839A1 (en) | 1998-11-05 |
Family
ID=21931638
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/006483 WO1998048839A1 (en) | 1997-04-30 | 1998-04-02 | Topical nasal antiinflammatory compositions |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0979105A1 (zh) |
JP (1) | JP2001524108A (zh) |
CN (1) | CN1253508A (zh) |
AU (1) | AU6878098A (zh) |
BR (1) | BR9809022A (zh) |
CA (1) | CA2281789A1 (zh) |
IL (1) | IL131492A0 (zh) |
WO (1) | WO1998048839A1 (zh) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999032125A1 (en) * | 1997-12-23 | 1999-07-01 | Schering Corporation | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine |
US6039974A (en) * | 1997-08-26 | 2000-03-21 | Hoechst Marion Roussel, Inc. | Pharmaceutical composition for combination of piperidinoalkanol-decongestant |
WO2000021510A2 (en) * | 1998-10-13 | 2000-04-20 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre, Ltd. | Formulations of fexofenadine |
WO2001007019A2 (en) * | 1999-07-27 | 2001-02-01 | Zambon Group S.P.A. | Use of n-acetyl-cysteine in the treatment of allergic pathologies of the respiratory tract |
DE10007203A1 (de) * | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
WO2003024433A2 (en) * | 2001-09-18 | 2003-03-27 | Nycomed Danmark Aps | Compositions for treatment of common cold, comprising ipratropium and xylometazoline |
GB2389530A (en) * | 2002-06-14 | 2003-12-17 | Cipla Ltd | Pharmaceutical composition comprising azelastine and steroid |
WO2005013963A1 (en) * | 2003-08-06 | 2005-02-17 | Galephar M/F | Advantageous combinations for inhalation of nacystelyn and bronchodilators |
JP2008013580A (ja) * | 1999-07-06 | 2008-01-24 | Naryx Pharma Inc | 副鼻腔炎を処置するためのエアロゾル化された抗感染剤、抗炎症剤および鬱血除去剤 |
US7879832B2 (en) | 2002-08-30 | 2011-02-01 | Nycomed Gmbh | Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
US8093301B2 (en) * | 2005-08-26 | 2012-01-10 | Meiji Co., Ltd. | Anti-allergic agent |
US8637469B2 (en) | 2006-07-11 | 2014-01-28 | Roy C. Levitt | Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors |
US9919050B2 (en) | 2004-11-24 | 2018-03-20 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine |
US9980959B2 (en) | 2004-05-11 | 2018-05-29 | Biolipox Ab | Method and composition for treating rhinitis |
US10064817B2 (en) | 2004-11-24 | 2018-09-04 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL373033A1 (en) * | 2002-06-20 | 2005-08-08 | Novartis Consumer Health S.A. | Nasal compositions comprising a mucopolysaccharide and propylene glycol |
JP4991693B2 (ja) * | 2005-03-16 | 2012-08-01 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤 |
JP2008143845A (ja) * | 2006-12-11 | 2008-06-26 | Hoshienu Seiyaku Kk | 点鼻薬組成物及び点鼻薬液噴霧器具 |
KR20150011807A (ko) * | 2012-05-25 | 2015-02-02 | 질리어, 인크. | 자일리톨계 항-점액성 조성물과 관련 방법 및 조성물 |
CN104667256B (zh) * | 2015-03-18 | 2017-05-03 | 江苏威克斯医疗科技有限公司 | 一种鼻腔粘膜纤毛护理冲洗液及其用途 |
CN107753485A (zh) * | 2017-11-28 | 2018-03-06 | 赵永宏 | 一种兼有鼻减充血和麻醉作用的药物组合物及其应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3482015A (en) * | 1965-02-08 | 1969-12-02 | Merck & Co Inc | Aerosol composition of phenylephrine tartrate and the production of such |
US4053628A (en) * | 1971-05-12 | 1977-10-11 | Fisons Limited | Composition |
WO1985004589A1 (en) * | 1984-04-09 | 1985-10-24 | Abraham Sunshine | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
JPS62153227A (ja) * | 1985-12-26 | 1987-07-08 | Sekisui Chem Co Ltd | 経皮・経粘膜製剤 |
WO1993009764A1 (en) * | 1991-11-19 | 1993-05-27 | Center For Innovative Technology | Combined virustatic antimediator (covam) treatment of common colds |
WO1995007103A1 (en) * | 1993-09-07 | 1995-03-16 | The Procter & Gamble Company | Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive |
WO1997001341A1 (en) * | 1995-06-29 | 1997-01-16 | Mcneil-Ppc, Inc. | The combination of topical nasal mast cell stabilizers and topical nasal steroids |
WO1997001337A1 (en) * | 1995-06-29 | 1997-01-16 | Mcneil-Ppc, Inc. | The combination of topical nasal antihistamines and topical nasal steroids |
WO1997009067A1 (de) * | 1995-09-05 | 1997-03-13 | Bayer Aktiengesellschaft | Kombination von 5-lipoxygenase- und leukotriensyntheseinhibitoren mit glucocorticosteroiden |
EP0780127A1 (en) * | 1995-12-19 | 1997-06-25 | The Procter & Gamble Company | A nasal spray containing a steroid and a antihistamine |
-
1998
- 1998-04-02 CN CN98804579A patent/CN1253508A/zh active Pending
- 1998-04-02 CA CA002281789A patent/CA2281789A1/en not_active Abandoned
- 1998-04-02 BR BR9809022-4A patent/BR9809022A/pt not_active Application Discontinuation
- 1998-04-02 IL IL13149298A patent/IL131492A0/xx unknown
- 1998-04-02 JP JP54699898A patent/JP2001524108A/ja active Pending
- 1998-04-02 WO PCT/US1998/006483 patent/WO1998048839A1/en not_active Application Discontinuation
- 1998-04-02 AU AU68780/98A patent/AU6878098A/en not_active Abandoned
- 1998-04-02 EP EP98914420A patent/EP0979105A1/en not_active Withdrawn
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3482015A (en) * | 1965-02-08 | 1969-12-02 | Merck & Co Inc | Aerosol composition of phenylephrine tartrate and the production of such |
US4053628A (en) * | 1971-05-12 | 1977-10-11 | Fisons Limited | Composition |
WO1985004589A1 (en) * | 1984-04-09 | 1985-10-24 | Abraham Sunshine | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
JPS62153227A (ja) * | 1985-12-26 | 1987-07-08 | Sekisui Chem Co Ltd | 経皮・経粘膜製剤 |
WO1993009764A1 (en) * | 1991-11-19 | 1993-05-27 | Center For Innovative Technology | Combined virustatic antimediator (covam) treatment of common colds |
WO1995007103A1 (en) * | 1993-09-07 | 1995-03-16 | The Procter & Gamble Company | Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive |
WO1997001341A1 (en) * | 1995-06-29 | 1997-01-16 | Mcneil-Ppc, Inc. | The combination of topical nasal mast cell stabilizers and topical nasal steroids |
WO1997001337A1 (en) * | 1995-06-29 | 1997-01-16 | Mcneil-Ppc, Inc. | The combination of topical nasal antihistamines and topical nasal steroids |
WO1997009067A1 (de) * | 1995-09-05 | 1997-03-13 | Bayer Aktiengesellschaft | Kombination von 5-lipoxygenase- und leukotriensyntheseinhibitoren mit glucocorticosteroiden |
EP0780127A1 (en) * | 1995-12-19 | 1997-06-25 | The Procter & Gamble Company | A nasal spray containing a steroid and a antihistamine |
Non-Patent Citations (1)
Title |
---|
DATABASE WPI Week 8733, Derwent World Patents Index; AN 87-230755, XP002067758 * |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6039974A (en) * | 1997-08-26 | 2000-03-21 | Hoechst Marion Roussel, Inc. | Pharmaceutical composition for combination of piperidinoalkanol-decongestant |
KR100737710B1 (ko) * | 1997-12-23 | 2007-07-11 | 쉐링 코포레이션 | 하나 이상의 류코트리엔 길항제와 데스카보에톡실로라티딘를 포함하는 호흡기 질환 및 피부 질환 치료용 조성물 |
AU758771B2 (en) * | 1997-12-23 | 2003-03-27 | Merck Sharp & Dohme Corp. | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine |
WO1999032125A1 (en) * | 1997-12-23 | 1999-07-01 | Schering Corporation | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine |
WO2000021510A2 (en) * | 1998-10-13 | 2000-04-20 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre, Ltd. | Formulations of fexofenadine |
WO2000021510A3 (en) * | 1998-10-13 | 2000-07-20 | West Pharm Serv Drug Res Ltd | Formulations of fexofenadine |
JP2008013580A (ja) * | 1999-07-06 | 2008-01-24 | Naryx Pharma Inc | 副鼻腔炎を処置するためのエアロゾル化された抗感染剤、抗炎症剤および鬱血除去剤 |
WO2001007019A2 (en) * | 1999-07-27 | 2001-02-01 | Zambon Group S.P.A. | Use of n-acetyl-cysteine in the treatment of allergic pathologies of the respiratory tract |
WO2001007019A3 (en) * | 1999-07-27 | 2001-09-27 | Zambon Spa | Use of n-acetyl-cysteine in the treatment of allergic pathologies of the respiratory tract |
DE10007203A1 (de) * | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
US6436924B2 (en) | 2000-02-17 | 2002-08-20 | Asta Medica Ag | Antihistamine leukotriene combinations |
US7652030B2 (en) | 2001-09-18 | 2010-01-26 | Nycomed Danmark Aps | Compositions for treatment of common cold |
WO2003024433A2 (en) * | 2001-09-18 | 2003-03-27 | Nycomed Danmark Aps | Compositions for treatment of common cold, comprising ipratropium and xylometazoline |
EP1661570A2 (en) * | 2001-09-18 | 2006-05-31 | Nycomed Danmark ApS | Compositions comprising ipatropium and xylometazoline for treatment of the common cold |
US8450339B2 (en) | 2001-09-18 | 2013-05-28 | Takeda Pharma A/S | Compositions for treatment of common cold |
EA008165B1 (ru) * | 2001-09-18 | 2007-04-27 | Никомед Данмарк Апс | Композиции для лечения простуды |
WO2003024433A3 (en) * | 2001-09-18 | 2004-06-10 | Nycomed Danmark Aps | Compositions for treatment of common cold, comprising ipratropium and xylometazoline |
EP1661570A3 (en) * | 2001-09-18 | 2012-10-24 | Nycomed Danmark ApS | Compositions comprising ipatropium and xylometazoline for treatment of the common cold |
US8304405B2 (en) | 2002-06-14 | 2012-11-06 | Cipla Limited | Combination of azelastine and ciclesonide for nasal administration |
US8933060B2 (en) | 2002-06-14 | 2015-01-13 | Cipla Limited | Combination of azelastine and ciclesonide for nasal administration |
US9901585B2 (en) | 2002-06-14 | 2018-02-27 | Cipla Limited | Combination of azelastine and fluticasone for nasal administration |
US9259428B2 (en) | 2002-06-14 | 2016-02-16 | Cipla Limited | Combination of azelastine and fluticasone for nasal administration |
US8163723B2 (en) | 2002-06-14 | 2012-04-24 | Cipla Limited | Combination of azelastine and steroids |
GB2389530A (en) * | 2002-06-14 | 2003-12-17 | Cipla Ltd | Pharmaceutical composition comprising azelastine and steroid |
US8937057B2 (en) | 2002-06-14 | 2015-01-20 | Cipla Limited | Combination of azelastine and mometasone for nasal administration |
US8318709B2 (en) | 2002-06-14 | 2012-11-27 | Cipla Limited | Combination of azelastine and mometasone for nasal administration |
GB2389530B (en) * | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
US8486923B2 (en) | 2002-08-30 | 2013-07-16 | Takeda Gmbh | Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
US7879832B2 (en) | 2002-08-30 | 2011-02-01 | Nycomed Gmbh | Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
EP2295062A1 (en) | 2002-08-30 | 2011-03-16 | Nycomed GmbH | The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
WO2005013963A1 (en) * | 2003-08-06 | 2005-02-17 | Galephar M/F | Advantageous combinations for inhalation of nacystelyn and bronchodilators |
US9980959B2 (en) | 2004-05-11 | 2018-05-29 | Biolipox Ab | Method and composition for treating rhinitis |
US9919050B2 (en) | 2004-11-24 | 2018-03-20 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine |
US10064817B2 (en) | 2004-11-24 | 2018-09-04 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
US8093301B2 (en) * | 2005-08-26 | 2012-01-10 | Meiji Co., Ltd. | Anti-allergic agent |
US8637469B2 (en) | 2006-07-11 | 2014-01-28 | Roy C. Levitt | Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors |
EP2851064A3 (en) * | 2006-07-11 | 2015-08-05 | Roy C. Levitt | Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors |
Also Published As
Publication number | Publication date |
---|---|
EP0979105A1 (en) | 2000-02-16 |
CN1253508A (zh) | 2000-05-17 |
IL131492A0 (en) | 2001-01-28 |
JP2001524108A (ja) | 2001-11-27 |
BR9809022A (pt) | 2000-08-01 |
CA2281789A1 (en) | 1998-11-05 |
AU6878098A (en) | 1998-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998048839A1 (en) | Topical nasal antiinflammatory compositions | |
EP1227812B1 (en) | Topical nasal treatment using desloratadine and mometasone furoate | |
AU651089B2 (en) | Treatment of sinus headache | |
EP1051155B1 (en) | Nasal solutions | |
JP4500045B2 (ja) | 感冒の治療のための組成物 | |
US20050281751A1 (en) | Directed intranasal administration of pharmaceutical agents | |
EP0780127A1 (en) | A nasal spray containing a steroid and a antihistamine | |
US20020193417A1 (en) | Nasal solutions | |
JPH11511758A (ja) | 鼻腔用ステロイドと抗ヒスタミン剤を含む鼻腔内噴霧薬 | |
AU2012216890A1 (en) | Combination of glycopyrrolate and a beta2 -agonist | |
SK283338B6 (sk) | Použitie mometazónfuroátu na prípravu liečiva na liečenie chorôb horných a dolných dýchacích ciest a pľúc | |
WO2004023984A2 (en) | Novel composition and method for treatment of upper respiratory conditions | |
JP2011520894A (ja) | 鼻性鼻炎の治療に使用するための組換えヒトcc10およびその組成物 | |
ES2740103T3 (es) | Uso de una composición que comprende formoterol y dipropionato de beclometasona para la prevención y/o el tratamiento de una exacerbación de asma | |
ES2340777T3 (es) | Metodo de tratamiento de la rinosinusitis aguda. | |
RU2005135332A (ru) | Назальные фармацевтические композиции и способы их применения | |
US4385048A (en) | Methods for the treatment of nasal hypersecretion | |
McAllen et al. | Intranasal flunisolide, placebo and beclomethasone dipropionate in perennial rhinitis | |
US7332528B2 (en) | DRI nasal sprays | |
MXPA99007597A (en) | Topical nasal antiinflammatory compositions | |
Martini et al. | Nasal and pulmonary drug delivery systems | |
US20020151562A1 (en) | Compositions and methods for treating allergic fungal sinusitis | |
WO2023144614A1 (en) | Nasal compositions and methods thereof | |
US20070140978A1 (en) | Adrenergic complement inhaler | |
WO2017201003A1 (en) | Materials and methods for treating chronic cough |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 131492 Country of ref document: IL Ref document number: 98804579.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BA BB BG BR CA CN CZ EE GE GW HU ID IL IS JP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2281789 Country of ref document: CA Ref document number: 2281789 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 68780/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/007597 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 337347 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 1998 546998 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998914420 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09423105 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998914420 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998914420 Country of ref document: EP |